Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities

Journal of Infection, Год журнала: 2023, Номер 87(2), С. e24 - e27

Опубликована: Май 17, 2023

Язык: Английский

---

Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study

EClinicalMedicine, Год журнала: 2024, Номер 69, С. 102468 - 102468

Опубликована: Фев. 9, 2024

BackgroundAzvudine and nirmatrelvir/ritonavir are approved to treat mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with a high risk for progression severe infection. We sought compare the antiviral effectiveness clinical outcomes of elderly patients COVID-19 receiving these two agents.MethodsIn this observational study, we identified 249 infection who were admitted Second Medical Center People's Liberation Army General Hospital from December 2022 January 2023, including 128 azvudine recipients, 66 recipients 55 not received treatments. compared cycle threshold (Ct) value dynamic change all three groups. The primary outcome was composite progression, all-cause death, intensive care unit admission, initiation invasive mechanical ventilation. enrolled followed up electronic medical record system. Kaplan–Meier Cox proportional regression analyses used To more directly drugs, performed propensity-score matching between groups efficacy matched population.FindingsAmong (mean age, 91.41 years), 77 died during follow-up period. When did receive any antivirals, neither nor demonstrated survival benefit. analysis death showed that 0.730 (0.423–1.262) group 0.802 (0.435–1.480) non-antiviral group. After propensity score matching, included 58 recipients. fitted curve Ct after illustrated rate viral decline early stage treatment seems surpass azvudine, but there no statistical significance. Azvudine seemly associated lower (HR:1.676, 95% CI:0.805–3.488) short-term (HR: 1.291, 95%CI: 0.546–3.051).InterpretationPatients have similar trend nirmatrelvir/ritonavir. In limited series, significant This lack benefit might be attributed potential bias.FundingThis study supported by "National Key R&D Program China" (Funding No. 2020YFC2008900) National Defense Science Technology Innovation Special Zone Project (223-CXCY-N101-07-18-01).

Язык: Английский

---

Effectiveness of azvudine in reducing mortality of COVID-19 patients: a systematic review and meta-analysis

Virology Journal, Год журнала: 2024, Номер 21(1)

Опубликована: Фев. 23, 2024

Abstract Background Azvudine has been approved for the treatment of coronavirus disease 2019 (COVID-19) patients in China, and this meta-analysis aims to illustrate safety azvudine its effectiveness reducing mortality. Methods PubMed, Embase, Web science, Cochrane Library Epistemonikos COVID-19 Living Overview Evidence database (L.OVE) were searched aggregate currently published studies. risk bias tool ROBINS-I used assess randomized controlled study cohort respectively. Odds radios (ORs) with 95% confidence interval (CIs) combined dichotomous variables. Publication was assessed by Egger’s test funnel plots. Results A total 184 articles retrieved from included databases 17 studies into final analysis. Pooled analysis showed that significantly reduced mortality compared controls (OR: 0.41, 95%CI 0.31–0.54, p < 0.001). Besides, either mild moderate or severe could benefit administration. There no significant difference incidence ICU admission 0.90, 0.47–1.72, = 0.74) invasive ventilation 0.94, 0.54–1.62, 0.82) between control group. The adverse events similar 1.26, 0.59–2.70, 0.56). Conclusions This suggests reduce patients, administration is acceptable. Trial registration PROSPERO; No.: CRD42023462988; URL: https://www.crd.york.ac.uk/prospero/ .

Язык: Английский

---

Azvudine reduces the in-hospital mortality of COVID-19 patients: A retrospective cohort study

Acta Pharmaceutica Sinica B, Год журнала: 2023, Номер 13(11), С. 4655 - 4660

Опубликована: Июль 13, 2023

In our retrospective cohort study, we aim to explore whether Azvudine modifies the risk of death in COVID-19 patients. It was conducted on medical records patients, consecutively admitted for pneumonia two hospitals Chongqing, China. Based treatment exposure, patients were divided into group and non-Azvudine group. We used 1:2 ratio propensity score matching (PSM) study adjust confounding factors differences between groups. There 1072 included original cohort. With PSM, 195 390 The results showed that associated with improved in-hospital mortality overall population (OR 0.375, 95% CI 0.225-0.623, P < 0.001), severe subgroup 0.239, 0.107-0.535, = critical 0.091, 0.011-0.769, 0.028) matched univariate analysis. And there a significantly lower (11% vs. 24%, P＜0.001), sub-group (10% 32%, 0.001) (5% 34%, 0.017) These suggest can reduce severe, population.

Язык: Английский

---

Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study

BMC Infectious Diseases, Год журнала: 2024, Номер 24(1)

Опубликована: Янв. 8, 2024

Abstract Background and aim Two oral antivirals (Nirmatrelvir- ritonavir Azvudine) are widely used in China practice during the Omicron wave of pandemic. However, little evidence regarding real-world effectiveness these two in-hospital patients. We aimed to evaluate clinical nirmatrelvir-ritonavir versus azvudine among adult hospitalized patients with COVID-19. Methods This retrospective cohort study data from three Chinese PLA General Hospital medical centres. Hospitalized COVID-19 treated or Dec 10, 2022, February 20, 2023, did not require invasive ventilation support on admission were eligible for inclusion. Results After exclusions propensity-score matching, final analysis included 486 recipients recipients. By 28 days initiation antivirus treatment, crude incidence rate all-cause death was similar both types treatment (nirmatrelvir-ritonavir group 2.8 events 1000 person-days [95% CI, 2.1–3.6] vs 3.4 events/1000 2.6–4.3], P = 0.38). Landmark showed that lower (3.5%) than (6.8%, 0.029) within initial 10-day period, while no significant difference observed results between 10 follow-up. There cumulative composite disease progression event (8.6% vs. 10.1% azvudine, HR, 1.22; 95% CI 0.80–1.86, 0.43). Conclusion Among omicron Beijing, outcomes receiving azvudine. it is worth noticing appears hold an advantage over reducing early mortality. Further randomized controlled trials needed verify efficacy those medications especially treatment.

Язык: Английский

---

Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients

BMC Infectious Diseases, Год журнала: 2024, Номер 24(1)

Опубликована: Янв. 3, 2024

Abstract Purpose To explore the effect of azvudine as compared to paxlovid for oral treatment hospitalized patients with SARS-CoV-2 infection. Methods We analyzed data from a cohort infection in Shandong provincial hospital between February 15 and March 15, 2023. The primary outcome was time sustained clinical recovery through Day 28 secondary outcomes included percentage participants who died any cause by 28, average hospitilization expenses, changes liver kidney function adverse events. Kaplan–Meier method Cox regression model used statistical analysis. Results There no significant difference terms ( p = 0.429) death rates 0.687). As hospitalization fee, differences were observed group (Hospitalization time: 0.633; Hospitalization fee: 0.820). In addition, there effects two drugs on > 0.05). Conclusion Among adults hospitalised infection, noninferior recovery, rates, cost, few safety concerns. Trial registration ChiCTR2300071309; Registered 11 May Level evidence III; Retrospective study.

Язык: Английский

---

Azvudine therapy of common COVID‐19 in hemodialysis patients

Journal of Medical Virology, Год журнала: 2023, Номер 95(8)

Опубликована: Июль 31, 2023

Abstract There is no antiviral study on hemodialysis patients infected with coronavirus disease 2019 (COVID‐19), especially the application of 2′‐deoxy‐2′‐β ‐fluoro‐4′‐azidocytidine (Azvudine, FNC) therapy. We conducted a multicenter observational involving 1008 patients. After matching for age, sex, and other factors, 182 in basic treatment group FNC were included. The negative nucleic acid conversion rate was significantly higher than that group, viral loads, interleukin‐6, C‐reactive protein lower those ( p < 0.05). significant differences liver function, renal or number adverse events between two groups > In conclusion, our has provided novel evidence suggesting scheme may be safe effective compared to common COVID‐19.

Язык: Английский

---

Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study

Infectious Diseases and Therapy, Год журнала: 2023, Номер 12(8), С. 2087 - 2102

Опубликована: Июль 24, 2023

Azvudine and nirmatrelvir-ritonavir are more extensively used to treat COVID-19 in China due their earlier approval by the National Medical Products Administration. However, there has been a scarcity of research directly comparing clinical outcomes between azvudine till now. We aimed make head-to-head comparison efficacy safety or hospitalized patients with China. This retrospective cohort study was conducted using data collected from Tongde Hospital Zhejiang Province December 2022 January 2023. All-cause mortality, risk progressing critical condition, proportion nucleic-acid negative conversion (PNANC), time first (TFNANC), length hospital stay incidence adverse events were systematically assessed as outcomes. Multi-model regression analysis, propensity-score-matching subgroup analysis several sensitivity analyses applied compare these included total 1571 COVID-19, among whom 272 received 156 azvudine. found no significant differences all-cause mortality (HR 1.41; 95% CI 0.56-3.56; P = 0.471), 1.67; 0.78-3.60; 0.189), PNANC 0.87; 0.69-1.09; 0.220), (β - 0.82; 2.78 1.15; 0.414) event rate (3.21% vs. 4.41%, 0.538) two groups, although slightly less effective than nirmatrelvir-ritonavir. Meanwhile, group exhibited significantly longer TFNANC 2.53; 0.76-4.29; 0.005) group. Results similar for propensity-score matching multiple analyses. probably possessed comparable nirmatrelvir-ritonavir, it some

Язык: Английский

---

Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study

Infection and Drug Resistance, Год журнала: 2023, Номер Volume 16, С. 6053 - 6060

Опубликована: Сен. 1, 2023

Nirmatrelvir-ritonavir, also known as paxlovid, is a widely used antiviral drug against coronavirus disease 2019 (COVID-19). Azvudine, previously to treat human immunodeficiency virus-1, has been COVID-19 in China. However, only few clinical studies have evaluated the effects of azvudine. Additionally, comparing nirmatrelvir-ritonavir with azvudine limited number.We carried out retrospective case‒control analysis at Third People's Hospital Tibet Autonomous Region. Eighty-two eligible patients who received treatment were included. A total 145 control selected by propensity score matching for age, sex, severity disease, and initial cycle threshold values. comparison nucleic acid test negative conversion time, length hospitalization, mortality rate was conducted.Overall, mean time comparable between groups (7.0 [11.0, 15.0] vs 9.0 [6.0, 12.0] days, P=0.064). mild COVID-19, significantly shorter group than (6.0 [5.0, 8.0] 8.0 11.0] P=0.029). The did not differ hospitalization (8.0 [5.5,10.5] [5.0,10.0] P=0.378). Regarding rate, there 4 (2.8%) deaths 3 (3.7%) (P=0.706).Azvudine generally effective nirmatrelvir-ritonavir, but could suppress virus more rapidly. For those cannot be treated might an therapy COVID-19.

Язык: Английский

---

Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study

Scientific Reports, Год журнала: 2024, Номер 14(1)

Опубликована: Фев. 9, 2024

Abstract This study aimed to explore the effectiveness and safety of azvudine, nirmatrelvir/ritonavir, molnupiravir in adult patients with mild-to-moderate COVID-19. retrospective cohort included COVID-19 (asymptomatic, mild, common types) at First Hospital Changsha (Hunan Province, China) between March November 2022. Eligible were classified into or groups according antiviral agents they received. The outcomes times nucleic acid negative conversion (NANC). 157 treated azvudine (n = 66), nirmatrelvir/ritonavir 25). There no statistically significant differences time from diagnosis NANC among molnupiravir, [median, 9 (95% CI 9–11) vs. 11 10–12) 8–12) days, P 0.15], administration 8–10) 10 9.48–11) 8.708 7.51–11) 0.50], hospital stay 11–13) 13 12–14) 12 10–14) 0.14], even after adjustment for sex, age, type, comorbidities, Ct level, treatment, number symptoms. cumulative rates 15.2%/12.3%/16.0% day 5 ( 0.858), 34.8%/21.5%/32.0% 7 0.226), 66.7%/52.3%/60.0% days 0.246), 86.4%/86.2%/80.0% 14 0.721). No serious adverse events reported. Azvudine may be comparable regarding NANC, stay, AEs.

Язык: Английский

---